ES2910374T3 - Formulaciones oftálmicas de cetirizina y procedimientos de uso - Google Patents

Formulaciones oftálmicas de cetirizina y procedimientos de uso Download PDF

Info

Publication number
ES2910374T3
ES2910374T3 ES10753927T ES10753927T ES2910374T3 ES 2910374 T3 ES2910374 T3 ES 2910374T3 ES 10753927 T ES10753927 T ES 10753927T ES 10753927 T ES10753927 T ES 10753927T ES 2910374 T3 ES2910374 T3 ES 2910374T3
Authority
ES
Spain
Prior art keywords
cetirizine
formulation
symptoms
formulations
ophthalmic formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10753927T
Other languages
English (en)
Spanish (es)
Inventor
Mark Abelson
Mathew Chapin
Paul Gomes
George Minno
Jackie Nice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox Ophthalmics Inc
Original Assignee
Nicox Ophthalmics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Ophthalmics Inc filed Critical Nicox Ophthalmics Inc
Application granted granted Critical
Publication of ES2910374T3 publication Critical patent/ES2910374T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES10753927T 2009-03-17 2010-03-15 Formulaciones oftálmicas de cetirizina y procedimientos de uso Active ES2910374T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16100609P 2009-03-17 2009-03-17
US17485009P 2009-05-01 2009-05-01
PCT/US2010/027295 WO2010107689A1 (en) 2009-03-17 2010-03-15 Ophthalmic formulations of cetirizine and methods of use

Publications (1)

Publication Number Publication Date
ES2910374T3 true ES2910374T3 (es) 2022-05-12

Family

ID=42738180

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10753927T Active ES2910374T3 (es) 2009-03-17 2010-03-15 Formulaciones oftálmicas de cetirizina y procedimientos de uso

Country Status (8)

Country Link
US (8) US9254286B2 (pt)
EP (2) EP3943069A1 (pt)
JP (8) JP6033677B2 (pt)
CA (1) CA2755679C (pt)
ES (1) ES2910374T3 (pt)
MX (1) MX2011009802A (pt)
PT (1) PT2408453T (pt)
WO (1) WO2010107689A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2910374T3 (es) * 2009-03-17 2022-05-12 Nicox Ophthalmics Inc Formulaciones oftálmicas de cetirizina y procedimientos de uso
US8569273B2 (en) * 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
CA2764473A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
KR101705032B1 (ko) 2010-05-12 2017-02-09 브룩스 오토메이션, 인크. 극저온 냉각용 시스템 및 방법
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
BR112014027681B8 (pt) 2012-05-08 2023-10-31 Aciex Therapeutics Inc Nanocristais de propionato de fluticasona, composição tópica farmacêutica compreendendo os mesmos, seu uso e método de fabricação
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
JP6843896B2 (ja) * 2017-02-13 2021-03-17 日東メディック株式会社 水性点眼点鼻用組成物
MX2019014748A (es) * 2017-06-08 2020-08-03 Eye Therapies Llc Combinaciones de brimonidina de dosis baja y usos de las mismas.
WO2019140403A1 (en) * 2018-01-15 2019-07-18 Seattle Gummy Company Semi-solid anti-histamine compositions and methods of making and using thereof
CN113712908A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 一种用于治疗过敏性结膜炎的组合物其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US610373A (en) 1898-09-06 Michele signorastbi
US569855A (en) 1896-10-20 Alvor butterfield
US452535A (en) 1891-05-19 Ehregott theodore winkler
US518882A (en) 1894-04-24 Mary p
US541989A (en) 1895-07-02 Joseph h
US440779A (en) 1890-11-18 Edward smith axd frederick smith
US643692A (en) 1899-09-27 1900-02-20 Bernard H Speckbauch Printing-press.
US682794A (en) 1899-12-19 1901-09-17 Friedrich August Gasch Process of obtaining zinc solutions free from iron and manganese compounds.
US664960A (en) 1900-09-05 1901-01-01 John A Hill Oil-separator and automatic regulating-valve for refrigerating systems.
FI75816C (fi) * 1981-02-06 1988-08-08 Ucb Sa Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
AU636685B2 (en) 1989-12-18 1993-05-06 Alcon Laboratories, Inc. Compositions of antiallergics and antihistamines and methods for their use
ATE170749T1 (de) 1992-09-24 1998-09-15 Sepracor Inc Verwendung von (-) cetirizin zur behandlung allergischer rhinitis und und asthma
TW401300B (en) 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
EP0954318A1 (en) 1996-06-04 1999-11-10 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
ATE314071T1 (de) 1996-08-16 2006-01-15 Schering Corp Behandlung von allergischen reaktionen im oberen respirationstrakt mit einer kombination von histamin-rezeptor-antagonisten
EP0903151A1 (en) * 1997-09-22 1999-03-24 ASTA Medica Aktiengesellschaft Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment of rhinitis/conjunctivitis and cold, cold-like and/or flu symptoms
US6103735A (en) 1998-10-09 2000-08-15 Schering Corporation Composition and method for treating allergic diseases
PL355101A1 (en) 1999-11-18 2004-04-05 Alcon Inc. Use of h1
DE10007203A1 (de) 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
JP2002025272A (ja) 2000-07-10 2002-01-25 Sharp Corp 半導体記憶装置およびその評価方法
AR035509A1 (es) 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
US7243343B2 (en) 2001-04-10 2007-07-10 International Business Machines Corporation Method, compiler and platform independent framework for parsing and generating data structures
US6985573B2 (en) 2001-04-13 2006-01-10 General Instrument Corporation Customer premises equipment that can support multiple call control languages or multiple call agents
US6592896B2 (en) 2001-08-06 2003-07-15 The Quigley Corporation Medicinal composition and method of using it
ATE317268T1 (de) 2001-12-05 2006-02-15 Alcon Inc Verwendung eines h1-antagonisten und von rimexolon als sicheres steroid zur behandlung von rhinitis
US6827946B2 (en) 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040019882A1 (en) 2002-07-26 2004-01-29 Haydt Robert J. Scalable data communication model
RU2220740C1 (ru) 2002-08-30 2004-01-10 Гапонюк Петр Яковлевич Средство для лечения аллергического ринита и аллергического конъюнктивита
JP2004168709A (ja) 2002-11-20 2004-06-17 Nidek Co Ltd 抗アレルギー点眼点鼻用組成物
WO2004069157A2 (en) 2003-01-17 2004-08-19 Ophthalmic Research Associates, Inc. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
WO2004066960A2 (en) 2003-01-28 2004-08-12 Schering Corporation Combination of h1, h3 and h4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
US20040198743A1 (en) 2003-01-31 2004-10-07 Schering Corporation Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists
US20050023974A1 (en) 2003-08-01 2005-02-03 Universal Display Corporation Protected organic electronic devices and methods for making the same
US20070027597A1 (en) 2003-09-23 2007-02-01 Daimlerchrysler Ag Method and device for recognising lane changing operations for a motor vehicle
US20060263350A1 (en) 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2005030331A1 (en) 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US20050239745A1 (en) 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
US8372814B2 (en) 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
PE20060484A1 (es) 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
JP3897777B2 (ja) 2004-07-23 2007-03-28 株式会社半導体理工学研究センター パルスベース通信システム
WO2006010294A1 (fr) 2004-07-26 2006-02-02 Quanta Display Inc. Dispositif d'affichage a cristaux liquides
US7307535B2 (en) 2004-07-27 2007-12-11 Datamars S.A. Air coil RF transponder and method of making same
US7337789B2 (en) 2004-07-27 2008-03-04 Minel Kupferberg Cleaning apparatus for exhaust system and method
CA2538865C (en) 2004-07-30 2011-03-29 Research In Motion Limited Method and apparatus for provisioning a communications client on a host device
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
JP2008534509A (ja) 2005-03-23 2008-08-28 エラン ファーマ インターナショナル リミテッド ナノ粒子副腎皮質ステロイドおよび抗ヒスタミン薬の製剤
JP2007012937A (ja) 2005-06-30 2007-01-18 Seiko Epson Corp 表示ドライバ
ES2498795T3 (es) 2005-09-01 2014-09-25 Meda Ab Composición de liposomas que contienen antihistamínicos y corticosteroides y su uso para la fabricación de un medicamento para tratar la rinitis y trastornos relacionados
ES2752823T3 (es) 2006-03-31 2020-04-06 Vistakon Pharmaceuticals Llc Tratamiento de alergias oculares
US20080008592A1 (en) 2006-06-27 2008-01-10 Societe De Commercialisation Des Produits De La Recherche Appliquee - Socpra-Sc Method and apparatus for controlling tonal noise from subsonic axial fans
KR100834625B1 (ko) 2006-07-27 2008-06-02 삼성전자주식회사 비디오 인코딩 데이터율 제어를 위한 실시간 장면 전환검출 방법
ES2624960T3 (es) 2006-09-29 2017-07-18 Johnson & Johnson Vision Care, Inc. Método de fabricación de dispositivos oftálmicos usados en el tratamiento de alergias oculares
WO2008127975A2 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
EP2173169B1 (en) * 2007-06-28 2014-05-21 CyDex Pharmaceuticals, Inc. Nasal delivery of aqueous corticosteroid solutions
ES2910374T3 (es) * 2009-03-17 2022-05-12 Nicox Ophthalmics Inc Formulaciones oftálmicas de cetirizina y procedimientos de uso

Also Published As

Publication number Publication date
JP2012520882A (ja) 2012-09-10
US20100240625A1 (en) 2010-09-23
JP2018141022A (ja) 2018-09-13
WO2010107689A1 (en) 2010-09-23
US9993471B2 (en) 2018-06-12
CA2755679C (en) 2017-09-12
PT2408453T (pt) 2022-04-05
US20160106666A1 (en) 2016-04-21
US20170182035A1 (en) 2017-06-29
MX2011009802A (es) 2011-11-02
JP2020117545A (ja) 2020-08-06
EP2408453A1 (en) 2012-01-25
CA2755679A1 (en) 2010-09-23
JP2016190878A (ja) 2016-11-10
EP3943069A1 (en) 2022-01-26
US20200297719A1 (en) 2020-09-24
US10675279B2 (en) 2020-06-09
US20200405711A1 (en) 2020-12-31
US11617749B2 (en) 2023-04-04
US9750684B2 (en) 2017-09-05
JP6893573B2 (ja) 2021-06-23
US20180280383A1 (en) 2018-10-04
JP7088980B2 (ja) 2022-06-21
JP6449202B2 (ja) 2019-01-09
US11918573B2 (en) 2024-03-05
JP6033677B2 (ja) 2016-11-30
US20130252971A1 (en) 2013-09-26
EP2408453A4 (en) 2013-08-28
JP2020117544A (ja) 2020-08-06
EP2408453B1 (en) 2022-01-05
US10987352B2 (en) 2021-04-27
JP2021138760A (ja) 2021-09-16
US9254286B2 (en) 2016-02-09
US20210290617A1 (en) 2021-09-23
JP2015007136A (ja) 2015-01-15
US8829005B2 (en) 2014-09-09
JP2016190879A (ja) 2016-11-10
JP6144393B2 (ja) 2017-06-07

Similar Documents

Publication Publication Date Title
ES2910374T3 (es) Formulaciones oftálmicas de cetirizina y procedimientos de uso
US20110105450A1 (en) Ophthalmic formulations of fluticasone and methods of use
US20100240624A1 (en) Ophthalmic Formulations of Ketotifen and Methods of Use
US8569273B2 (en) Ophthalmic formulations of cetirizine and methods of use